reports
Sensus Healthcare Reports First Quarter 2024 Financial Results With Re...
Sensus Healthcare Reports First Quarter 2024 Financial Results With Revenues up More than Three-fold Revenues of $10.7 million, compared with $3.4 million in the prior-year quarter; Adjusted EBITDA (a non-GAAP measure) of $3.0 million, compared with negative $2.7 million in the prior-year quarterLaunched the “Fair Deal Agreement” recurring revenue program to provide an equipment placement option and complement the fair market value lease program for SRT systems Conference call begins at 4:30 p.m. Eastern time today BOCA RATON, Fla., May 09, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, In...
Largest Veterinary Emergency Hospital in Tel Aviv Acquires Sensus Heal...
Largest Veterinary Emergency Hospital in Tel Aviv Acquires Sensus Healthcare’s SRT-100™ to Provide Gentler Radiotherapy to Treat Tumors in Dogs and Cats First veterinary commercial sale of the SRT-100 outside the U.S. BOCA RATON, Fla., May 09, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces the sale of an SRT-100 system to Chavat Da’at, the Veterinary Specialist Referral Center Knowledge Farm a...
Noodles & Company Announces First Quarter 2024 Financial Results
Noodles & Company Announces First Quarter 2024 Financial Results BROOMFIELD, Colo., May 08, 2024 (GLOBE NEWSWIRE) -- Noodles & Company (Nasdaq: NDLS) today announced financial results for its first quarter ended April 2, 2024. Key highlights for the first quarter of 2024 versus the first quarter of 2023 include: Total revenue decreased 3.7% to $121.4 million from $126.1 million in the first quarter of 2023.Comparable restaurant sales decreased 5.4% system-wide, comprised of a 5.7% decrease at company-owned restaurants and a 4.5% decrease at franchise restaurants.Net loss was $6.1 mi...
Terns Pharmaceuticals Announces Leadership Changes
Terns Pharmaceuticals Announces Leadership Changes FOSTER CITY, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced the appointment of Scott Harris as chief development officer (CDO) effective May 28, 2024 and the upcoming departure of Erin Quirk, M.D., president, head of research and development. Dr. Quirk will be transitioning her responsibilities and...
- Blair Levin
- Jonathan Chaplin
Terns Pharmaceuticals to Participate in The Citizens JMP Life Sciences...
Terns Pharmaceuticals to Participate in The Citizens JMP Life Sciences Conference 2024 FOSTER CITY, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that members of senior management will be participating in a fireside chat at The Citizens JMP Life Sciences Conference 2024 on Tuesday, May 14, 2024 at 1:30 p.m. ET. A live webcast of the fireside chat...
Propetro Holding Corp: 1 director
A director at Propetro Holding Corp sold 42,573 shares at 9.280USD and the significance rating of the trade was 66/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cl...
Sensus Healthcare Announces Sale of First SRT-100 Vision™ System to As...
Sensus Healthcare Announces Sale of First SRT-100 Vision™ System to Asia Reminder: First Quarter 2024 Financial Results Reporting and Conference Call on May 9, 2024 BOCA RATON, Fla, May 06, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces the sale of the first SRT-100 Vision™ (IG-SRT) system in Asia, to Far Eastern Memorial Hospital in Taiwan. The hospital, which has more than 1,000 beds, is one of the largest private ho...
- Jonathan Chaplin
Autumn for Broadband 1Q24
In this installment of our Autumn for Broadband series, we provide a quick update on trends in the broadband market based on what we have seen from the companies that have reported so far. Industry net adds were substantially weaker in 1Q24 with all technologies seeing slower growth (except DSL which was flat). Cable was impacted the most.
Terns Pharmaceuticals Reports Inducement Grant to New Employee Under N...
Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4) FOSTER CITY, Calif., May 03, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that it has granted as of May 1, 2024 an equity inducement award to Melita Sun Jung, the Company’s new Chief Business Officer, under the terms of the 2022 Employment Inducement Award Plan, a...
Terns Pharmaceuticals Announces Data from Ongoing Phase 1 Pharmacokine...
Terns Pharmaceuticals Announces Data from Ongoing Phase 1 Pharmacokinetic Study of Allosteric BCR-ABL Inhibitor TERN-701 in Adult Healthy Volunteers and Highlights Potential for Competitive Differentiation Ability to dose TERN-701 without regard to food represents a key potential differentiator within the allosteric BCR-ABL inhibitor class Pharmacokinetic data show no clinically significant difference in exposure between fed and fasted dosing Phase 1 CARDINAL trial evaluating TERN-701 in 2L+ CML patients remains ongoing, with interim data from initial cohorts anticipated in second half of...
- Blair Levin
NSR Policy: The Interconnections of ACP, Spectrum, Title II, and the S...
In this weekend update, we reconsider our initial takes on several events last week and how they could be affected by events this week. Specifically, we look at the interplay of the FCC’s Title II Order, the Second Circuit opinion upholding New York State’s mandate for ISPs to offer low-income households a low-cost broadband offering, Senator Cantwell’s draft spectrum bill, and how all are affected by the end of ACP funding in the next few weeks.
Sensus Healthcare Issues Reminder That its First Quarter 2024 Financia...
Sensus Healthcare Issues Reminder That its First Quarter 2024 Financial Results and Business Update Conference Call Will be Held on Thursday, May 9, 2024 BOCA RATON, Fla., April 25, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, reminds investors that management will hold a conference call on Thursday, May 9, 2024 at 4:30 p.m. Eastern time to discuss the financial results for the first quarter of 2024. In addition, management will provid...
- Jonathan Chaplin
AT&T Model Update
What's new: This note covers changes to the model after results. We increased postpaid phone adds, FWA adds, Consolidated EBITDA, and FCF slightly. We also lowered fiber adds slightly. Consensus EBITDA likely increases, with a more valuable business mix. No change to thesis. Neutral: $21 (+30% total return).
- Jonathan Chaplin
AT&T: quick thoughts following the call
What’s new: we start with a diatribe focused on the improving quality of the business, of management’s decisions, and of disclosure (with small suggestions for further improvements). We then touch on AT&T’s FWA strategy and its implications for others, the impact of Gigapower on fiber trends and the prospect of seeing other Broadband companies pursuing a similar strategy, what we learned about broadband market growth (which is less than we had hoped), what we learned about wireless market growth...
- Jonathan Chaplin
AT&T 1Q24 Quick Take
What’s new: Service revenue was almost in-line, EBITDA beat, but EPS was in-line, and FCF beat (mostly timing). By segment: wireless service revenue was a hair soft, but EBITDA beat handily. Phone adds beat on much lower-than-expected churn. Consumer Wireline revenue was roughly in-line while EBITDA beat handily. Fiber adds were in-line (preannounced), while Internet Air adds were well ahead of estimates. Business Wireline missed on service revenue and EBITDA.
Sensus Healthcare to Host First Quarter 2024 Financial Results and Bus...
Sensus Healthcare to Host First Quarter 2024 Financial Results and Business Update Conference Call on Thursday, May 9, 2024 BOCA RATON, Fla. , April 18, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that management will hold a conference call on Thursday, May 9, 2024 at 4:30 p.m. Eastern time to discuss the financial results for the first quarter of 2024. In addition, management will provide a business update and a discussion ...
Noodles & Company to Announce First Quarter 2024 Results on May 8, 202...
Noodles & Company to Announce First Quarter 2024 Results on May 8, 2024 BROOMFIELD, Colo., April 18, 2024 (GLOBE NEWSWIRE) -- Noodles & Company (NASDAQ: NDLS) today announced that it will host a conference call to discuss its first quarter 2024 financial results on Wednesday, May 8, 2024 at 4:30 p.m. ET. Drew Madsen, Chief Executive Officer, and Mike Hynes, Chief Financial Officer, will host the call. A press release with first quarter 2024 financial results will be issued after the market close that same day. To access the live conference call, please click on the registration link t...
Monarch Casino & Resort Reports Record First Quarter 2024 Financial Re...
Monarch Casino & Resort Reports Record First Quarter 2024 Financial Results Declares Cash Dividend of $0.30 per Share Payable on June 15, 2024 RENO, Nev., April 17, 2024 (GLOBE NEWSWIRE) -- Monarch Casino & Resort, Inc. (Nasdaq: MCRI) (“Monarch,” “we,” “our,” or “the Company”) today reported operating results for the first quarter ended March 31, 2024, as summarized below: ($ in thousands, except per share data and percentages) Three Months Ended March 31, 2024 2023 IncreaseNet revenue $121,657 $116,644 4.3% Net income 18,275 17,670 3.4% Adjusted EBITDA (1) $38,548 $36,480 5....
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.